Assessment of US Pharmacies Contracted With Health Care Institutions Under the 340B Drug Pricing Program by Neighborhood Socioeconomic Characteristics
- PMID: 35977245
- PMCID: PMC9206190
- DOI: 10.1001/jamahealthforum.2022.1435
Assessment of US Pharmacies Contracted With Health Care Institutions Under the 340B Drug Pricing Program by Neighborhood Socioeconomic Characteristics
Abstract
This cross-sectional study assesses pharmacy participation in the 340B Drug Pricing Program following the 2010 expansion and the extent to which growth has occurred in socioeconomically disadvantaged neighborhoods.
Copyright 2022 Lin JK et al. JAMA Health Forum.
Conflict of interest statement
Conflict of Interest Disclosures: Dr Li reported personal fees from HealthStatistics LLC and Covia Health Solutions outside the submitted work. Dr Doshi reported grants from Humana, Janssen, Merck, Novartis, PAN Foundation, Regeneron, and Sanofi, and personal fees from AbbVie, Acadia, Boehringer Ingelheim, Catabasis, Janssen, MeiraGTx, Merck, Otsuka, SAGE Therapeutics, Takeda, and The Medicines Company, all unrelated to and outside the submitted work. No other disclosures were reported.
Figures

Similar articles
-
Trends in 340B Drug Pricing Program Contract Growth Among Retail Pharmacies From 2009 to 2022.JAMA Health Forum. 2023 Aug 4;4(8):e232139. doi: 10.1001/jamahealthforum.2023.2139. JAMA Health Forum. 2023. PMID: 37540525 Free PMC article.
-
The 340b Program, Contract Pharmacies, Hospitals, and Patients: An Evolving Relationship Impacting Health Care Delivery.Health Care Manag (Frederick). 2019 Oct/Dec;38(4):311-321. doi: 10.1097/HCM.0000000000000279. Health Care Manag (Frederick). 2019. PMID: 31663869
-
Challenges for Managed Care from 340B Contract Pharmacies.J Manag Care Spec Pharm. 2016 Mar;22(3):197-203. doi: 10.18553/jmcp.2016.22.3.197. J Manag Care Spec Pharm. 2016. PMID: 27003548 Free PMC article.
-
340B Drug Pricing Program and hospital provision of uncompensated care.Am J Manag Care. 2021 Oct;27(10):432-437. doi: 10.37765/ajmc.2021.88761. Am J Manag Care. 2021. PMID: 34668672 Free PMC article.
-
A comparison of medication access services at 340B and non-340B hospitals.Res Social Adm Pharm. 2021 Nov;17(11):1887-1892. doi: 10.1016/j.sapharm.2021.03.010. Epub 2021 Mar 20. Res Social Adm Pharm. 2021. PMID: 33846100 Review.
Cited by
-
340B Contract pharmacy growth by pharmacy ownership: 2009-2022.Health Aff Sch. 2023 Dec 9;2(1):qxad075. doi: 10.1093/haschl/qxad075. eCollection 2024 Jan. Health Aff Sch. 2023. PMID: 38756399 Free PMC article.
-
The Association of 340B Program Drug Margins with Covered Entity Characteristics.Inquiry. 2025 Jan-Dec;62:469580251324051. doi: 10.1177/00469580251324051. Epub 2025 Mar 23. Inquiry. 2025. PMID: 40123227 Free PMC article.
-
Trends in 340B Drug Pricing Program Contract Growth Among Retail Pharmacies From 2009 to 2022.JAMA Health Forum. 2023 Aug 4;4(8):e232139. doi: 10.1001/jamahealthforum.2023.2139. JAMA Health Forum. 2023. PMID: 37540525 Free PMC article.
-
Assessing the Impact of the 340B Drug Pricing Program: A Scoping Review of the Empirical, Peer-Reviewed Literature.Milbank Q. 2024 Jun;102(2):429-462. doi: 10.1111/1468-0009.12691. Epub 2024 Jan 28. Milbank Q. 2024. PMID: 38282421 Free PMC article.
-
The 340B Program and High-Risk Prescribing of Oral Targeted Therapies for Advanced Prostate Cancer.Urol Pract. 2024 Nov;11(6):931-938. doi: 10.1097/UPJ.0000000000000655. Epub 2024 Jun 26. Urol Pract. 2024. PMID: 39196717
References
-
- Notice regarding 340B drug pricing program-contract pharmacy services. Fed Regist. 2010;75(43):10272-10279. Accessed May 9, 2022. https://www.govinfo.gov/app/details/FR-2010-03-05/2010-4755/summary